Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
Stephen Jones
STEPHEN JONES, US Oncology Research, Houston
Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.
Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/071213_stephen_jones.mp3]
